Position in BMY
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$5,639,211
-$621,870 QoQ
Shares Held
97,869
-5.2% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.72%
of 13F equity value
Holder Rank
#517
of 2,506 holders
Holding Since
Mar 2020
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BMY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026LEUTHOLD GROUP, LLC holds $50,589,532 across 8 Drug Manufacturers - General names. BMY ranks #6 (11.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
31,085 | $7,894,657 | |
| 2 | AMGN |
Amgen Inc
|
20,512 | $7,427,805 | |
| 3 | BIIB |
Biogen Inc.
|
31,489 | $6,803,513 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
53,031 | $6,699,936 | |
| 5 | MRK |
Merck & Co., Inc.
|
47,803 | $6,142,685 | |
| 6 | BMY |
Bristol Myers Squibb Co
This page
|
97,869 | $5,639,211 | |
| 7 | GSK |
GSK plc
|
97,182 | $5,094,280 | |
| 8 | PFE |
Pfizer Inc
|
202,967 | $4,887,445 |
All Filings in BMY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,639,211 | 97,869 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $6,261,081 | 103,233 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $5,449,288 | 101,025 | Shares | Sole | 2026-02-05 | |
| 2023-06-30 | $330,109 | 5,162 | Shares | Sole | 2023-08-08 | |
| 2023-03-31 | $357,778 | 5,162 | Shares | Sole | 2023-04-18 | |
| 2022-12-31 | $392,631 | 5,457 | Shares | Sole | 2023-02-07 | |
| 2022-09-30 | $393,625 | 5,537 | Shares | Sole | 2022-10-31 | |
| 2022-06-30 | $426,349 | 5,537 | Shares | Sole | 2022-08-01 | |
| 2020-09-30 | $428,300 | 7,104 | Shares | Sole | 2020-11-16 | |
| 2020-06-30 | $429,357 | 7,302 | Shares | Sole | 2020-08-14 | |
| 2020-03-31 | $422,955 | 7,588 | Shares | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||